In 2005, the International Society for Heart and Lung Transplantation published a standardized definition of primary graft dysfunction (PGD), facilitating new knowledge on this form of acute lung injury that occurs within 72 h of lung transplantation. PGD continues to be associated with significant morbidity and mortality. This article will summarize the current literature on the epidemiology of PGD, pathogenesis, risk factors, and preventive and treatment strategies.
INTRODUCTION
Primary graft dysfunction (PGD) after lung transplantation is a significant source of early morbidity and mortality [1] [2] [3] [4] [5] [6] [7] . We will review recently published literature on the epidemiology, pathogenesis, risk factors, prevention, and treatment of PGD.
DEFINITION
PGD, a form of acute lung injury occurring within 72 h of lung transplantation, is characterized by hypoxemia and alveolar infiltrates in the allograft [2] . Early case reports of postoperative allograft dysfunction used different criteria to define the syndrome and referred to it by various names [4, [8] [9] [10] [11] [12] . In 2005, the International Society for Heart and Lung Transplantation (ISHLT) standardized the definition of PGD, permitting consistent classification of this clinical syndrome [2] . PGD is now graded based on PaO 2 /FiO 2 (P/F) and the presence of radiographic infiltrates in the allograft consistent with pulmonary edema. The definition also requires exclusion of contributing factors, including hyperacute rejection, pulmonary venous anastomotic obstruction, cardiogenic edema, and pneumonia [2] . The severity of PGD is reassessed daily up to 72 h after reperfusion (Table 1) . Grade 3 PGD (PGD3) corresponds to a P/F of less than 200 with allograft infiltrates, on extracorporeal membrane oxygenation (ECMO) or ventilated with FiO 2 above 0.5 and on iNO [2] .
PGD3 occurring at any time point after reperfusion is associated with greater alteration in plasma markers of lung injury and higher 30-day mortality compared to those with lower grades [1] . However, even among patients with PGD3, there is variability in the duration of pulmonary edema and patient mortality [13] , leading to a belief that separate endotypes may be indicative of differences in injury response. In 2015, the ISHLT began a second consensus effort to update and refine the PGD definition; therefore, updated criteria should be forthcoming addressing issues including timing of PGD onset and resolution, precision of the P/F at different levels of FiO 2 , single versus bilateral transplants, and differences in grading fibrotic lung disease patients.
EPIDEMIOLOGY AND OUTCOMES
Since 2005, the incidence of PGD3 at a single time point has been reported to be 7.9% and 25%, whereas the incidence of PGD3 at any time point during the first 3 days is approximately 30% [1, 5, 7, [14] [15] [16] [17] . The variability is likely attributable to differences in institutional practices and risk factor distributions.
PGD is associated with significant early and late posttransplant morbidity. Regardless of the time point of grading, PGD3 has been associated with significantly longer hospital length of stay, duration of mechanical ventilation, and 90-day mortality than those with lower grades of PGD [1, 4, 5, 14, 16, 17] . PGD3 present at 48 or 72 h after transplantation was associated with an 18% increased absolute risk of 90-day mortality [14] , with increased mortality persisting at 1, 5, and 10 years after transplantation [5, 7, [14] [15] [16] [17] . In addition, all PGD is associated with elevated risk of bronchiolitis obliterans syndrome (BOS), a form of chronic allograft dysfunction [5, 7, 15, 16] . Future mechanistic trials are needed to understand the relationship between PGD and the development of BOS.
PATHOGENESIS
PGD represents the end result of multiple deleterious mechanisms provoked by donor brain death, mechanical ventilation, procurement, storage, and ischemia reperfusion injury (IRI). IRI refers to sterile inflammation that occurs after substrate supply is restored following a period of absent blood flow [18 & ]. Although many mechanisms are at play, recent studies highlight the importance of the interplay between innate immune activation, epithelial cell injury, endothelial cell dysfunction, and cytokine release [19] ( Table 2 ).
INNATE IMMUNE ACTIVATION
Upregulation of innate immune pathways, including toll-like receptors (TLR) and nucleotide-binding oligomerization-like receptor inflammasome signaling, has been demonstrated in-vivo animal models following IRI and in human patients with PGD [35] [36] [37] [38] [40] [41] [42] [43] [44] [45] [46] [47] . Animal models suggests that IRI occurs in two phases mediated in part by a bimodal response by the innate immune system with donor macrophages and lymphocytes inducing the early phase and recipient monocytes, T-cells, and neutrophils inducing the late phase [40] [41] [42] [43] [44] [45] [46] [47] .
A family of innate immune cells, innate lymphoid cells (ILCs) have recently been recognized for their role in inflammation regulation, barrier protection and repair, and host defense. Although ILCs have lymphoid morphology, they lack antigen receptors and can be subdivided based on cytokine expression and function [39,48 & ,49 ]. Group 2 ILCs (ILC2) produce type 2 T-helper cell-associated cytokines and have been isolated in both human blood and lung, suggesting a trafficking ability. In animal
KEY POINTS
Although the annual number of lung transplantations is increasing, PGD following lung transplantation remains a significant source of short-and long-term morbidity and mortality.
The pathogenesis of PGD remains poorly understood, but is likely the end result of multiple deleterious mechanisms provoked by donor brain death, mechanical ventilation, procurement, storage, and ischemia-reperfusion injury.
Better understanding of the role of established clinical risk factors, as well as the emerging data on the importance of innate immunity, epithelial cell injury, endothelial cell dysfunction, and cytokine production in the development of PGD is necessary in order to identify potential high-risk populations and therapeutic targets.
Future trials should focus on identifying appropriate patients to bridge to transplant with extracorporeal life support and expanding the donor pool with extracorporeal lung perfusion without increasing the risk of PGD. Table 1 . Grading system for primary graft dysfunction (PGD) [2] models, ILC2 cells appear to play an important role in airway epithelial integrity and airway remodeling [39] . Isolation of ILC2 cells in bronchoalveolar lavage of transplant recipients warrants further exploration of the role of ILCs and other innate immune cells in PGD [39] .
EPITHELIAL CELL INJURY
Numerous markers of epithelial cell injury have also been associated with PGD in both animal and human studies, including receptor for advanced glycation end products (RAGE), type V collagen, and plasma clara cell secretory protein [20-25, [50] [51] [52] . The role of traumatic brain injury (TBI) in the development of epithelial cell injury and IRI has been of increasing interest as the majority of lungs used for transplantation are procured from patients who have suffered TBI. High-mobility group box protein 1 (HMGB1) is a danger-associated molecular pattern released from necrotic neurons after TBI as well as alveolar macrophages after IRI. 
ENDOTHELIAL DYSFUNCTION
Endothelial dysfunction in lung IRI typically results mostly from disruption and restoration of blood flow with minimal contribution from tissue hypoxia and reoxygenation as the lung does not rely on perfusion for oxygenation [18 & ]. Changes in blood flow during ischemia lead to closure of inward-rectifying potassium channels and subsequent endothelial cell depolarization [54] [55] [56] . This depolarization results in production of reactive oxygen species (ROS) and nitric oxide [57] [58] [59] [60] , increasing cell adhesion molecules for leukocyte adhesion and extravasation and activating NF-KB and other transcription factors [18 & ,59,61 && ]. Subsequent reperfusion results in hyperpolarization of endothelial cells and activation of a similar cascade as ischemia, the end result of which is further oxidative injury [62] . Future potential targets to modify endothelial activation and decrease PGD may include maintenance of lung TLR4 mutations associated with innate immune hyporesponsiveness were associated with a lower PGD risk [36] Higher plasma PTX3 levels were seen in those with grade 3 PGD [37] Single nucleotide polymorphisms associated with higher levels of PTX3 were associated with grade 3 PGD [38] Innate lymphoid cells were isolated from BAL of lung transplant recipients [39] Adapted with permission [19] . BAL, bronchoalveolar lavage; CC16, plasma clara cell secretory protein; ET-1, endothelin-1; HMGB1, high-mobility group box-1; IP-10, interferon-inducible protein; MCP-1, monocyte chemotactic protein-1; P/F, PaO 2 /FiO 2 ; PAI-1, plasminogen activator inhibitor-1; PGD, primary graft dysfunction; PTX3, long pentraxin-3; RAGE, receptor for advanced glycation end products; TLR, toll-like receptor; VEGF, vascular endothelial growth factor.
perfusion with extracorporeal lung perfusion, administration of potassium channel agonists, and inhibition of ROS production [18 & ,63]. In addition to inducing oxidative injury, disruption in blood flow to the lung may disrupt the endothelial cell barrier and induce vascular remodeling. Sphingosine 1-phosphate (S1P) controls endothelial cell tight junction formation and prevents chemotaxis. S1P supplementation prior to reperfusion decreased inflammatory cytokines and improved oxygenation in animal models [64,65 & ]. Several animal and human studies have demonstrated an association between IRI and mediators of vascular permeability and angiogenesis including vascular endothelial growth factor and angiopoietin-2 [27-30, [66] [67] [68] . Further trials are needed to explore the role of IRI on endothelial integrity and vascular remodeling.
CHEMOTAXIS AND CYTOKINES
In many solid organ models, IRI has been shown to stimulate the release of proinflammatory cytokines as well as chemokines involved in migration of recipient immune cells including IL-1b, IL-6, IL-8, IL-11, interferon-gamma, and tumor necrosis factor (TNF)-a [ 
CLINICAL RISK FACTORS
Many groups have studied PGD risk factors (Table 3) 
DONOR-RELATED CLINICAL RISK FACTORS
Reported donor risk factors include age, African American race, female sex, and history of tobacco exposure (Table 3) [101] . In donor lungs deemed unsuitable for transplantation, pulmonary edema and IL-8 were higher in donors who currently smoked although alveolar fluid clearance was lower in donors with greater than 20-pack year history compared to those with a less than 20-pack year history, suggesting a possible dose-related effect [102 && ]. The impact of donor smoke exposure on PGD risk is difficult to ascertain as individual studies use different smoking cut-offs, and smoking status is obtained from surrogates. Further studies are needed to clarify the role of donor smoke exposure on PGD. A recent study using registry data suggested that although donor smoke exposure was associated with worse recipient outcomes, the survival probability after receiving such an allograft still exceeded that of remaining on the waiting list [103] .
Donor-acquired risk factors, including prolonged mechanical ventilation, aspiration, and trauma, are potential risk factors without definitive studies demonstrating consistent associations with PGD [81] . Efforts are needed to standardize donor management and to optimize donor-recipient matching.
RECIPIENT-RELATED RISK FACTORS
Reported recipient risk factors for PGD include obesity, pulmonary hypertension, and diagnoses of idiopathic pulmonary fibrosis or sarcoidosis ( Table 3 ) [6, 11, 14, 79, 80, 82, 89, 97, 98, 100] . After adjustment for multiple risk factors, obese and overweight recipient BMI were independent predictors of PGD. Higher levels of leptin, which regulates adipose tissue mass and has inflammatory properties, were also associated with increased PGD risk and mortality [97] . This supports previous studies showing obesity increases the risk of acute lung injury [104, 105] . Although increasing adiposity is associated with PGD, it is unclear how best to assess body composition given a recent study demonstrating that BMI is a poor measure of adiposity [106 && ]. Following identification of a reliable measure of body composition, future studies should evaluate the role of adipokines in cytokine release and PGD.
PERIOPERATIVE RISK FACTORS
The operative risk factors for PGD reported in multicenter cohort studies are single lung transplant procedure type, prolonged ischemic time, cardiopulmonary bypass (CPB) use, greater than 1L packed red blood cell transfusion volume, use of Euro-Collins preservation solution, and reperfusion FiO 2 greater than 0.4 (Table 3) [12, 14, 82, 87, 89, 90, 95, 96] . Oversized allografts have been associated with a decreased risk of PGD3 and improved survival in bilateral lung transplant recipients, especially in recipients without chronic obstructive pulmonary disease [107,108 && ]. Significant operative variability exists across transplant centers making it difficult to identify consistent operative risk factors. Confounding by disease severity or treatment indication further complicates the study of operative risk factors. Future trials should distinguish between emergent and planned use of CPB, evaluate the effect of lower reperfusion FiO 2 on PGD, and explore the mechanisms by which the above operative factors increase PGD risk.
PREVENTION AND TREATMENT
Several agents have been investigated to prevent PGD [109] . Although some observational trials of inhaled nitric oxide (iNO) suggest improved clinical outcomes, randomized control trials failed to show a definitive effect of iNO on PGD prevention when used routinely [110] [111] [112] [113] [114] [115] [116] . Soluble complement receptor 1 inhibitor, plasminogen-activating factor antagonist, and exogenous surfactant demonstrated beneficial effects on surrogates of PGD including A-a gradient [117] [118] [119] [120] . A trial of aprotinin failed to detect an effect on PGD risk and was stopped early out of concern for potential renal toxicity [121] . Clearly, additional trials on PGD prevention are needed.
Therapy for PGD remains largely supportive and is heavily influenced by acute respiratory distress syndrome management strategies. Although most centers use low-stretch ventilation, tidal volumes are frequently selected based on recipient characteristics with little consideration given to donor characteristics [122 & ,123 & ,124] . Although there is no proven role for iNO in the prevention of PGD, it has been used as salvage therapy for severe allograft dysfunction following transplant and may be useful in patients with refractory hypoxemia posttransplant [125] [126] [127] .
Veno-arterial ECMO has been studied for refractory hypoxemia and hemodynamic instability after lung transplant [128] [129] [130] [131] [132] [133] [134] . Given the link between CPB use and PGD, several groups have evaluated replacing CPB intraoperatively with veno-arterial ECMO with mixed results [135, 136, 137 && ]. Venoarterial ECMO has been associated with shorter duration of mechanical ventilation and ICU/hospital length of stay, and lower transfusion requirements, but no statistically significant difference in 90-day mortality [137 && ]. With improvement in ECMO technology, including high performance membranes and coated circuits, veno-venous ECMO has been increasingly used with similar posttransplant outcomes and survival as veno-arterial ECMO [131, 135] . Several groups have evaluated the use of extracorporeal life support (ECLS) with venovenous, veno-arterial, and arterio-venous ECMO as a bridge to lung transplantation. Future research is needed to identify optimal candidates, standardize management strategies, and understand the impact of ECLS ]. A portable extracorporeal lung perfusion device was created to minimize ischemic time. Although case reports of this portable extracorporeal perfusion system are promising [160, 161] , the results of randomized control trials are pending [162, 163] . Extracorporeal lung perfusion may eventually allow well tolerated expansion of the donor pool and serve as a vehicle for testing targeted therapeutics to improve organ quality and decrease PGD risk. Several multicenter prospective trials are underway to further evaluate this technology, with PGD as an endpoint.
CONCLUSION
PGD is associated with poor short-term and longterm outcomes. The ISHLT definition has improved our ability to study this clinical syndrome, but further refinement of the definition is still needed and should be forthcoming. Improved understanding of risk factors and pathogenesis will identify potential therapeutic targets to modify the risk of PGD. As the acceptable recipient pool likely expands secondary to increasing ECLS use, continued well tolerated expansion of the donor pool must follow and may be possible given the promising results seen with extracorporeal lung perfusion. Blockade of RAGE and neutralization of HMGB1 attenuated acute lung injury due to TBI in an animal model, and elevated donor HMGB1 was associated with lower P/F after transplantation. These findings suggest that the HMGB1-RAGE axis plays a role in lung dysfunction after brain death, which has important implications for donation after brain determination of death. This case report describes the use of venovenous extracorporeal membrane oxygenation as a bridge to lung transplantation in a patient recovering from acute respiratory distress syndrome. 141.
